Sareum Share Discussion Threads

[norma_stitts] 27/6/2022 12:11

Meanwhile on Nonce Island thedarkhalfwit has hooked up with Jasmine.

Viewers were left amazed at his lack of singing ability when he woke her up with breakfast in bed - a packet of Haribo Tangfastics, then proceeded to serenade her with a DJ Sammy classic;

thedarkhalfwit;
Baby you’re all that I want
When you’re lying here in my arms
I’m finding it hard to believe you’re eleven

[gekko2023] 27/6/2022 11:51

Once again all the 737 chatter is a red hearing and LSE goes quiet...no RNS and no news...wasn't June supposed to be a news filled month for us?! No Froth2 telling us that a TO is happening...keep dreaming fellas..xx

[thedarkhalf] 27/6/2022 11:02

Sorry to hear that SGH. Who will read to you now?

[silvergreyhead1] 27/6/2022 10:55

No doubt you do Barkboo, but treasure them always. We lost our little one two weeks ago. The other one is very down on certain walks always looking round for her.

[horridhenry] 27/6/2022 10:39

The happy slappers elsewhere, and here(steadydanny)spouting complete nonsense over the weekend (no doubt alcohol induced)

There is nothing to show or prove that anything with GSK is imminent. Links from as far back as 2019 support nothing but desperation

It's a waiting game.

I'll have a bet with you steadydanny that there will be no RNS this week

[gekko2023] 27/6/2022 08:30

Annnnddddd..the share price falls again...MrsRapesLapdog...DarkPoo..anything you would like to add...ahouldnt our share price be rising giving the imminent takeover? xx

[barkbooo] 27/6/2022 08:14

Have just taken my dogs for a waddle up the lane - hope to take them for a walk Wednesday?

[yzf750] 26/6/2022 22:46

Jam tomorrow it is then Great find critical

[criticalthinker1] 26/6/2022 22:33

Maybe it's been in trials elsewhere
A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.

Udai Banerji, Elizabeth Ruth Plummer, Victor Moreno, Joo Ern Ang, Amy Quinton, Yvette Drew, Tatiana Hernández, Desamparados Roda, Louise Carter, Alejandro Navarro, Rebecca Sophie Kristeleit, Hendrik-Tobias Arkenau, Debashis Sarker, Daniel E. Castellano, Harriet Walter, Patricia Roxburgh, Sarah Patricia Blagden, Alan Anthoney, Ines Verdon, Robert Hugh Jones
Drug Development Unit-The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Northern Centre for Cancer Care, Newcastle-upon-Tyne, United Kingdom; START Madrid - FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom; Velindre Cancer Centre, Cardiff, United Kingdom; Newcastle University, Northern Institute for Cancer Research, Newcastle-upon-Tyne, United Kingdom; Hospital Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria INCLIVA, Valenica, Spain; The University of Manchester, Manchester, United Kingdom; Vall d'Hebron University Hospital/Vall d´Hebron Institute Oncolgy (VHIO), Barcelona, Spain; University College London Hospitals, London, United Kingdom; Sarah Cannon Research Institute, Cancer Institute, University College London, London, United Kingdom; King's College Hospital, Institute of Liver Studies, London, United Kingdom; Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain; University of Leicester, Leicester, United Kingdom; University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; University of Oxford, Oxford, United Kingdom; St James's Institute of Oncology, St. James's University Hospital, West Yorkshire, United Kingdom; Sierra Oncology Inc., Vancouver, BC, Canada
Checkout the first name Udai and the very last company name Sierra Oncology. Those who know know.
If this week is not pivotal I will call my dog a duck.
Regards Steadydanny

[criticalthinker1] 26/6/2022 21:44

. Conclusions: In this first-in-human trial of SRA737 monotherapy, the MTD was 1000 mg/day and based on overall tolerability and PK, the recommended Phase 2 dose is 800 mg/day. The successful enrollment of prospectively-selected genetically-defined subjects will allow response data to be correlated with genomic profiles hypothesized to confer sensitivity to Chk1 inhibition. Clinical trial information: NCT02797964
Not long posted to the www. IN HUMAN! FFS! Never a time have I seen a requirements for a Norwich Pharmacal Order that is itching to be put forward. This could well scupper the GSK deal. GSKs due diligence lawyers need to be on this.

I hope sareum bod are on this tomorrow.
I also hope SO shareholders read this. Chk1 about to hit proverbial fan.
Regards Steadydanny

[criticalthinker1] 26/6/2022 19:57

Hi gekko appreciate your response. So re your comment on secret patents...would that not dovetail given the timelines of what SO has effectively been doing re a media blackout on 737 and where we have effectively gained worldwide protection for some of our other ipr recently.
All within the radio silence period of 737.
Don't forget 1802 is very similar to 1801 and could be a pipeline candidate for another party whilst we undertake 1801 trials.
Anyway like you say let's see.
Regards Steadydanny

[gekko2023] 26/6/2022 19:32

Hi CriticalThinker it's the usual jam tomorrow...yes, it sounds good...Just like secret patents etc...but nothing changes.. i am cynical...Happy to be proven wrong..we shall see.. xx

[criticalthinker1] 26/6/2022 19:20

Gekko are you not slightly thinking OMG that I pulled up that 737 has had inhuman trials ( will find the report again but looked like GB and Spain...something like 130 and 38 patients respectively) since 2019? So I thought a payment was due.
And that Norma pointed out that apparently the contract states that certain locations for testing avoid the payment.
Dosnt it seem to you that just possibly the GSK purchase of SO is DEFINITELY not solely for momo!?
Correct me if I'm wrong but if this information such as this is discussed then the board have a duty of obligation to respond...and I believe if something is happening in the background they are bound by NDAs and then it falls upon a Sareum NED to address information that has 'the interests of shareholders' to be responded to.
Tomorrow could be tumbleweed whilst the ducks are put in a row or maybe Tuesday for news.

[gekko2023] 26/6/2022 18:53

Froth2/MrsApesLapdog appears to have gone silent across all BBs when I schooled him as to why a TO can't be on progress...probs crying into some wotsits whilst telling folks he's a prince....xx

[gekko2023] 26/6/2022 12:51

Norma...where do you see Mondays share price .are we close to the 28p party? XX

[criticalthinker1] 25/6/2022 21:52

2021...
Niraparib caused a significant increase in oxidative stress, and induced activation of DNA damage markers, phosphorylation of CHK2 and replication fork stalling. Importantly, niraparib, in combination with gemcitabine, produced sustained and robust inhibition of tumor growth in vivo in a patient-derived xenograft (PDX) model more effectively than either treatment alone. Furthermore, tissue samples from mice treated with niraparib and gemcitabine display significantly lower expression levels of pHH3 and Ki-67, which are a mitotic and proliferative marker, respectively. Taken together, our results indicate niraparib as a novel therapeutic agent alone or in combination with gemcitabine for CCA.

Mark my words DDR is going to heard more frequently.
See you all on Monday